查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
軸性脊柱關節炎治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按療法、按適應症、按終端用戶、按公司和按地區分類
市場調查報告書
商品編碼
1289641

軸性脊柱關節炎治療市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按療法、按適應症、按終端用戶、按公司和按地區分類

Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Indication, By End User, By Company, and By Region
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球軸性脊柱關節炎治療市場預計將在2023-2027年預測期內觀察到令人矚目的成長。主要因素包括軸性脊柱關節炎發病率的上升和公眾對該疾病認知的提高，都推動了市場的成長。軸性脊柱關節炎是一種影響軸性骨骼的慢性炎症性疾病。患者會因此而經歷嚴重的不適，背部僵硬，以及疲勞。支持市場成長的其他因素有：世界人口成長、研究活動增加、病人數量激增、大量臨床試驗、產品創新和開發增加、對研究和開發的大量投資、人均醫療保健支出增加、軸突性關節炎患病率增加、合併和收購數量增加，以及一些當局對改善現有醫療保健基礎設施的重視。

軸性脊柱關節炎發病率的激增

全球範圍內軸性脊柱關節炎發病率的增加正在推動市場的成長。軸性脊柱關節炎的病因尚不清楚，但經過多次研究，人們認為它是由於基因暴露於某些細菌、病毒或其他觸發因素而引起的。患者會經歷嚴重的不適，如受影響部位的僵硬和疲勞。不僅是老年人群，年輕一代也很容易患上這種疾病。因此，這些因素正在推動全球市場的成長。根據一項引用的研究，在美國，大約有270萬美國人或更多的人受到軸突性關節炎（axSpA）的影響。

獲得批准的生物學名藥的數量增加

根據世界衛生組織（WHO），生物學名藥是指在安全、品質和療效方面與已經獲得許可的原始生物治療產品相似的生物治療產品。生物學名藥是有助於治療軸性脊柱關節炎等疾病的生物藥物。它們對病人非常有效，由於其更容易獲得，已經取代了原研藥。在過去的幾年裡，獲准用於治療軸性脊柱關節炎的生物學名藥數量激增，這正在促進全球市場的成長。例如，在2020年和2021年，美國食品和藥物管理局批准了三種新型產品，即Xeljanz、Taltz和Cosentyx，以治療軸突性關節炎患者。

不斷增加的研發活動

分子和免疫學領域的研究和開發（R&D）活動的增加正在推動市場的成長。由於研究活動的增加，新型生物製劑的出現，如腫瘤壞死因子（TNF）抑製劑、IL-23和白細胞介素（IL）-17抑製劑正在猛增。例如，2022年，全球生物製藥公司UCB宣布了積極的頂線中期分析結果，顯示3期BE MOBILE 1研究達到了主要和所有排名第二的終點。 BE MOBILE 1是衡量bimekizumab在患有活動性非放射狀軸性關節炎（nr-axSpA）的成人中的有效性和安全性的主要研究。此外，政府對研究活動的投資增加也促進了市場的成長。

可用的定製服務

利用給定的市場數據，TechSci Research根據公司的具體需求提供定製服務。該報告有以下定製選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和簡介。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球軸性脊柱關節炎治療市場的影響

第五章：客戶的聲音

第六章：臨床試驗分析

第七章：全球軸突性脊柱關節炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按療法分類（抗腫瘤壞死因子（TNF）療法、抗白細胞介素（IL）療法、抗雅努斯激酶（JAK）療法）
    • 按適應症（強直性脊柱炎和/或非放射型軸索性脊柱關節炎治療）
    • 按終端用戶（醫院和診所、學術和研究機構、其他）分類
    • 按地區
    • 按公司分類(2021年)
  • 市場地圖

第八章：北美軸突性脊柱關節炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按療法分類
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 美國
    • 墨西哥

第九章：歐洲軸突性脊柱關節炎治療市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按療法分類
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第十章：亞太地區軸性脊柱關節炎治療市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按療法分類
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第11章：南美軸性脊柱關節炎治療市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按療法分類
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第十二章：中東和非洲軸性脊柱關節炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按療法分類
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類
  • MEA: 國家分析
    • 南非軸突性脊柱關節炎的治療
    • 沙烏地阿拉伯軸突性脊柱關節炎的治療
    • 阿拉伯聯合大公國軸突性脊柱關節炎的治療

第十三章：市場動態

  • 驅動力
  • 挑戰

第十四章：市場趨勢與發展

第十五章：競爭格局(包括SWOT分析)

  • 諾華國際公司（Novartis International, AG
  • 禮來公司
  • 強生公司
  • UCB SA
  • 輝瑞公司（Pfizer, Inc.
  • 京華麒麟股份有限公司
  • 默克公司（Merck & Co.
  • 艾伯維公司
  • Bristol-Myers Squibb公司
  • FunPep有限公司

第16章：戰略建議

簡介目錄
Product Code: 13053

The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of axial spondyloarthritis and increasing public awareness of the disease, are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market's growth are the growing world population, increasing research activities, a surge in the number of patients, a large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.

A surge in Incidences of Axial Spondylarthritis

The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).

Increase in the Number of Approved Biosimilars

According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.

Increasing R&D Activities

Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.

Market Segmentation

The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.

Market Players

Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.

Report Scope

In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Axial Spondyloarthritis Treatment Market, By Therapy:

  • Anti-Tumor Necrosis Factor (TNF) Therapy
  • Anti-Interleukin (IL) Therapy
  • Anti-Janus Kinase (JAK) Therapy

Axial Spondyloarthritis Treatment Market, By Indication:

  • Ankylosing Spondylitis
  • Non-radiographic Axial Spondyloarthritis Treatment

Axial Spondyloarthritis Treatment Market, By End User:

  • Hospitals & Clinics
  • Academic & Research Institutions
  • Others

Axial Spondyloarthritis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Axial Spondyloarthritis Treatment Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Axial Spondyloarthritis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
    • 7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
    • 7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2021)
  • 7.3. Market Map

8. North America Axial Spondyloarthritis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User

9. Europe Axial Spondyloarthritis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User
    • 9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By End User
    • 9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By End User

10. Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User
    • 10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Therapy
        • 10.3.4.2.2. By Indication
        • 10.3.4.2.3. By End User
    • 10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Therapy
        • 10.3.5.2.2. By Indication
        • 10.3.5.2.3. By End User

11. South America Axial Spondyloarthritis Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By End User
    • 11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By End User
    • 11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By End User

12. Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Therapy
    • 12.2.2. By Indication
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Therapy
        • 12.3.1.2.2. By Indication
        • 12.3.1.2.3. By End User
    • 12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Therapy
        • 12.3.2.2.2. By Indication
        • 12.3.2.2.3. By End User
    • 12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Therapy
        • 12.3.3.2.2. By Indication
        • 12.3.3.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

  • 15.1. Novartis International, AG
  • 15.2. Eli Lilly and Company
  • 15.3. Johnson & Johnson
  • 15.4. UCB S.A.
  • 15.5. Pfizer, Inc.
  • 15.6. Kyowa Kirin Co., Ltd.
  • 15.7. Merck & Co., Inc.
  • 15.8. AbbVie Inc
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. FunPep Co., Ltd.

16. Strategic Recommendations